Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAR-TREC rectal-sparing strategies vs total mesorectal excision in early rectal cancer
2019-004669-41Phase 3Active
- Sponsor
- University of Birmingham
- Start
- Dec 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of capecitabine in rectal cancer (3 arms), sponsored by University of Birmingham. Primary endpoints: Organ preservation rate, Toxicity (clinician-reported) and 2 more. Started Dec 2019; status: active.
02
Drugs
capecitabine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on 2019-004669-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004669-41.